Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.

All rankings and data on Wootrader are purely for informational purposes. None of the information on this site should be construed as advice to 'buy' or 'sell' stocks. If you are trading stocks, you are always at risk of losing value. There is no guarantee that any of our top ranked stocks will perform well in the market. Although we made every effort to ensure the accuracy of the available data, Wootrader Inc. and involved data providers shall not be liable for any errors or delays in the content, or for any actions taken based on the content.